-
Tytuł:
-
Botulinum toxin therapy in the SARS-CoV-2 pandemic: patient perceptions from a German cohort.
-
Autorzy:
-
Dressler D; Movement Disorders Section, Department of Neurology, Hannover Medical School, Carl-Neuberg-Str. 1, 30625, Hannover, Germany. .
Adib Saberi F; IAB-Interdisciplinary Working Group for Movement Disorders, Hamburg, Germany.
-
Źródło:
-
Journal of neural transmission (Vienna, Austria : 1996) [J Neural Transm (Vienna)] 2020 Sep; Vol. 127 (9), pp. 1271-1274. Date of Electronic Publication: 2020 Jul 30.
-
Typ publikacji:
-
Journal Article
-
Język:
-
English
-
Imprint Name(s):
-
Original Publication: Wien ; New York : Springer-Verlag, 1996-
-
MeSH Terms:
-
Betacoronavirus*
Pandemics*/prevention & control
Patient Satisfaction*
Ambulatory Care Facilities/*trends
Botulinum Toxins, Type A/*administration & dosage
Coronavirus Infections/*epidemiology
Pneumonia, Viral/*epidemiology
Aged ; COVID-19 ; Cohort Studies ; Female ; Germany/epidemiology ; Humans ; Male ; Middle Aged ; Neuromuscular Diseases/drug therapy ; Neuromuscular Diseases/epidemiology ; Neuromuscular Diseases/psychology ; SARS-CoV-2 ; Surveys and Questionnaires
-
References:
-
Dressler D, Adib Saberi F (2005) Botulinum toxin: mechanisms of action. Eur Neurol 53:3–9. (PMID: 10.1159/000083259)
Niedersächsisches Gesetz- und Verordnungsblatt (2020a) Niedersächsische Verordnung zur Bekämpfung der Corona-Virus-Krankheit COVID-19. 21067 (neu). Niedersächsisches Gesetz- und Verordnungsblatt, 74. Jahrgang, Nummer 4, 19.03.20, S:37–37.
Niedersächsisches Gesetz- und Verordnungsblatt (2020b) Niedersächsische Verordnung zur Bekämpfung der Corona-Virus-Krankheit COVID-19. 21067. Niedersächsisches Gesetz- und Verordnungsblatt, 74. Jahrgang, Nummer 12, 05.05.20, S:90–93.
-
Contributed Indexing:
-
Keywords: Botulinum toxin; COVID19; Corona virus; Dystonia; Hemifacial spasms; Pain conditions; Pandemic; Patient rights; Perception; Quality of life; SARS-CoV-2; Spasticity; Therapy
-
Substance Nomenclature:
-
EC 3.4.24.69 (Botulinum Toxins, Type A)
-
Entry Date(s):
-
Date Created: 20200801 Date Completed: 20200826 Latest Revision: 20210619
-
Update Code:
-
20240104
-
PubMed Central ID:
-
PMC7391233
-
DOI:
-
10.1007/s00702-020-02235-6
-
PMID:
-
32734554
-
The SARS-CoV-2 virus pandemic has provoked drastic countermeasures including shutdowns of public services. We wanted to describe the effects of a 6 week shutdown of a large German botulinum toxin (BT) outpatient clinics on patients and their well-being. 45 patients (age 61.9 ± 9.8 years, 29 females, 16 males) receiving BT therapy (319.3 ± 201.9MU-equivalent, treatment duration 8.3 ± 5.5 years) were surveyed with a standardised questionnaire. The shutdown delayed BT therapy by 6.6 ± 2.3 weeks. 93% of the patients noticed increased muscle cramps and 82% increased pain reducing their quality of life by 40.2 ± 19.5%. For 23 patients with cervical dystonia this reduction was 41.1 ± 18.3%, for 3 patients with blepharospasm 33.3 ± 15.3%, for 9 patients with spasticity 37.8 ± 15.6%, for 4 patients with pain conditions 37.4 ± 35.7% and for 3 patients with hemifacial spasm 27.5 ± 17.1%. After the shutdown 66% of patients perceived BT therapy as more important than before, 32% perceived it as unchanged. For all patients long-term availability of BT therapy was very important or important. 98% of the patients perceived the shutdown as inadequate and felt their patient rights not respected. The shutdown confirmed the considerable burden of disease caused by dystonia, spasticity, hemifacial spasm and various pain conditions and the importance of BT therapy to treat them. Any shutdown severely affects these patients and needs to be avoided.